PEARL-HF: Prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016

Future Cardiology

Volumn 8, Issue 1, 2012, Pages 17-28

  Buysse, Jerry M ^a   Huang, I Zu ^a   Pitt, Bertram ^b  

^a Vifor (International) Inc   (Switzerland)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

aldosterone; aldosterone receptor antagonist; chronic kidney disease; heart failure; hyperkalemia; renin angiotensin aldosterone system; serum potassium

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CANDESARTAN; CATION EXCHANGE RESIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRON; MAGNESIUM; PATIROMIR; PHOSPHOROUS ACID; PLACEBO; POLYMER; POLYSTYRENESULFONATE CALCIUM; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SODIUM; SPIRONOLACTONE; VALSARTAN;

ALBUMINURIA; ANOREXIA; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES IMPACTION; FLATULENCE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IRON BLOOD LEVEL; MAGNESIUM BLOOD LEVEL; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; TREATMENT DURATION; VOMITING;

AGED; ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; POLYMERS; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 84555197132     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.71     Document Type: Review

References (42)

1. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999). (Pubitemid 29407370)
2. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003). (Pubitemid 36384098)
3. Zannad F, McMurray JVJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
4. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur. Heart J. 30, 469-477 (2009).
5. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N. Engl. J. Med. 351, 585-592 (2004).
6. Preston RA, Afshartous D, Garg D et al. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 53, 754-760 (2009).
7. Sica DA. The risks and benefts of therapy with aldosterone receptor antagonist therapy. Curr. Drug Saf. 2, 71-77 (2007). (Pubitemid 46723171)
8. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Rev. 10, 23-29 (2005). (Pubitemid 40895313)
9. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study N. Engl. J. Med. 351, 543-551 (2004). (Pubitemid 39025171)
10. Pitt B, Anker SD, Bushinsky DA et al. Evaluation of the effcacy and safety off RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32, 820-828 (2011).
11. Cope J, Biyani K, Chan H-T et al. RLY5016, a new effective, non-absorbed, therapeutic polymer to control serum potassium. Presented at: American Society of Nephrology Annual Meeting. F-PO1616. Denver, CO, USA, 16-21 November 2010.
12. Huang I-Z, Blok T, Burdick M et al. RLY5016, a novel, non-absorbed, therapeutic polymer for the control of serum potassium: Phase 1 studies. Presented at: American Society of Nephrology Ann ual Meeting. F-PO1615. Denver, CO, USA, 16-21 November 2010.
13. Brown RS. Potassium homeostasis and clinical implications. Am. J. Med. 77(5A), 3-10 (1984). (Pubitemid 15222750)
14. Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 107, 548-571 (1994). (Pubitemid 24233333)
15. Gennari FJ. Hypokalemia. N. Engl. J. Med. 339, 451-458 (1998). (Pubitemid 28377688)
16. Sandle GI, Hunter M. Apical potassium (BK) channels and enhanced potassium secretion in human colon. Q. J. Med. 103, 85-89 (2010).
17. Sorensen MV, Matos JE, Praetorius HA et al. Colonic potassium handling. Eur. J. Physiol. 459, 645-656 (2011).
18. Mathialahan T, MacIennan KA, Sandle LN et al. Enhanced large intestinal potassium permeability in end-stage renal disease. J. Pathol. 206, 46-51 (2005). (Pubitemid 40613433)
19. Sandle GI, Gaiger E, Tapster S et al. Enhanced rectal potassium excretion in chronic renal insuffciency: evidence for large intestinal potassium adaptation in man. Clin. Sci. 71, 393-401 (1986). (Pubitemid 16012438)
20. Sorensen MV, Strandsby AB, Larsen CK et al. The secretory KCa1. 1 channel localizes to crypts of distal mouse colon: functional and molecular evidence. Pfugers Arch. Eur. J. Physiol. 462(5), 745-752 (2011).
21. + secretion. J. Physiol. 586, 4251-4264 (2008).
22. Sandle GI, Gaiger E, Tapster S et al. Evidence for large intestinal control of potassium homeostasis in uraemic patients undergoining long-term dialysis. Clin. Sci. 73, 247-252 (1987). (Pubitemid 17095101)
23. Mathialahan T, Sandle GI. Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease. Nephrol. Dial. Transplant. 18, 341-347 (2003). (Pubitemid 36181686)
24. Bushinsky DA, Huang I-Z, Anker SD et al. A novel, effective, non-absorbed, oral polymer for the control of serum potassium in HF and CKD. Presented at: American Society of Nephrology Annual Meeting. F-PO 1617 Denver, CO, USA, 16-21 November 2010.
25. Kessler C, Ng J, Valdez K et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J. Hosp. Med. 6, 136-140 (2011).
26. Pitt B, Bakris G, Ruilope LM et al. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure effcacy and survival study (EPHESUS). Circulation 118, 1643-1650 (2008).
27. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr. Heart Fail. Reports 6, 272-280 (2009).
28. Abdo AS, Basu A, Geraci SA. Managing chronic heart failure patient in chronic kidney disease. Am. J. Med. 124, 26-28 (2011).
29. Einhorn LM, Zhan M, Hsu VD et al. The frequency of hyperkalemia and its signifcance in chronic kidney disease. Arch. Intern. Med. 169, 1156-1162 (2009).
30. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 30, 418-424 (2009).
31. Poggio R, Grancelli HO, Miriuka SG. Understanding the risk of hyperkalemia in heart failure: role of aldosterone antagonism. Postgrad. Med. J. 86, 136-142 (2010).
32. Cavallari LH, Groo VL, Viana MAG et al. Association of aldosterone concentration and mineral ocorticoid receptor genotype with potassium response to spirnonolactone in patients with heart failure. Pharmacotherapy 30, 1-9 (2010).
33. Scherr L, Ogden DA, Mead AW et al. Management of hyperkalemia with a cation-exchange resin. N. Engl. J. Med. 264, 115-119 (1961).
34. Sterns RH, Rojas M, Bernstein P et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J. Am. Soc. Nephrol. 21, 733-735 (2010).
35. Flinn RB, Merrill JP, Welzan WR. Treatment of the oliguric patient with a new sodium ion-exchange resin and sorbitol: a preliminary report. N. Engl. J. Med. 264, 111-115 (1961).
36. Gruy-Kapral C, Emmett M, Santa Ana CA et al. Effect off single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J. Am. Soc. Nephrol. 9, 1924-1930 (1998). (Pubitemid 28443490)
37. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am. J. Cardiol. 78, 902-907 (1996).
38. Palmer BF. Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease. Am. J. Nephrol. 28, 381-390 (2008). (Pubitemid 351501603)
39. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169), 2001-2007 (1999).
40. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772-776 (2003). (Pubitemid 37093917)
41. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325(5), 293-302 (1991).
42. Bowling CB, Pitt B, Ahmed MI et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: fndings from propensity-matched studies. Circ. Heart Fail. 3, 253-260 (2010).